Status:

COMPLETED

Study of Oxycyte in Severe Closed Head Injury

Lead Sponsor:

Tenax Therapeutics, Inc.

Collaborating Sponsors:

Virginia Commonwealth University

Conditions:

Traumatic Brain Injury

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

Brain damage as a result of decreased oxygen to the brain is found in 80% of patients that die with severe head injuries. Laboratory studies in animals and clinical trials have shown that increasing o...

Detailed Description

Decreased brain oxygen in severe brain injuries appears to be implicated in poor functional outcome and death. Animal and clinical studies have shown that increasing brain oxygen in such patients impr...

Eligibility Criteria

Inclusion

  • severe closed head injury patients or GCS 3-9 patients who receive brain oxygen monitoring
  • ventriculostomy/ICP monitor
  • at least one reactive pupil
  • no known life threatening disease prior to trauma
  • age 18-70 years old
  • consent for microdialysis/brain 02 monitoring
  • legal family representative present that can give informed consent for perfluorocarbon administration

Exclusion

  • no motor response
  • both pupils fixed and dilated
  • no consent available
  • allergy to egg proteins
  • coagulopathy
  • major liver injury
  • major pulmonary injury

Key Trial Info

Start Date :

September 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2008

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT00174980

Start Date

September 1 2005

End Date

July 1 2008

Last Update

June 10 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Virginia Commonwealth University Medical Center

Richmond, Virginia, United States, 23298